Preclinical models for pulmonary disease and drug delivery
map

The Allergenix sheep models of respiratory disease provide a platform for realistic in vivo drug discovery studies and preclinical testing in a highly translational large animal model system.

These models have been used to improve understanding of the pathways underlying human disease pathogenesis, and to discover more effective therapies to prevent or halt the progression of disease.

Sheep model of allergic asthma (proprietary Allergenix model)

  • induced by active sensitisation and lung challenge with house dust mite (HDM), the most prominent human allergen: acute and chronic models of disease
  • characterised by: Th2 immune profile; eosinophil inflammation, mast cells; airway wall remodelling (chronic); decline in lung function (chronic)
  • responsive to (human) anti-asthma medications
  • customised model system: whole lung or targeted segmental lobes for challenge and/or treatment studies
  • model potential: disease pathogenesis studies; efficacy of anti-asthma treatments/therapies

Sheep model of COPD/emphysema

  • induced by lung exposures to elastase and LPS
  • characterised by: neutrophil and macrophage inflammation; tissue damage consistent with emphysema (enlargement of air spaces and alveolar wall destruction); lung function decline
  • model potential: disease pathogenesis studies; efficacy of treatments/therapies to alter inflammation, and rate of tissue destruction and lung function decline

Sheep model of pulmonary fibrosis

  • induced by lung exposures to bleomycin
  • characterised by: inflammation; fibrosis and collagen deposition; lung function decline
  • responsive to (human) anti-fibrosis medications
  • model potential: disease pathogenesis studies; therapeutic intervention studies to change the course of fibrosis and rate of lung function decline

Other sheep respiratory disease models

  • acute lung inflammation: based on LPS lung administration -
  • current projects in development include: sheep respiratory virus (RSV) infection model; sheep lung adenocarcinoma model
  • capacity to develop unique models with unmet needs

 

 

Pulmonary drug administration

In vivo capabilities

In vitro and ex vivo capabilities